Neuropathic Pain, Genetic Predisposition, Polyneuropathies
Conditions
Keywords
reliability, validity
Brief summary
In the present study the investigators will search for new genetic variants relevant for the development of neuropathic pain.
Detailed description
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain is a huge health problem worldwide, with an estimated prevalence of 7-8 % in the general population. In the present study the investigators will search for new genetic variants relevant for the development of this type of pain. Peripheral nerve lesions only progress to neuropathic pain in some patients, yet is not completely understood why or how. Genetic studies of patients with rare neuropathic disorders have been important for elucidating novel molecular mechanisms of neuropathic pain, and new drugs for neuropathic pain are now being developed based on these findings. By using genetic association studies, one may identify new genetic variants which may help to identify key molecular mechanisms for a larger group of patients with neuropathic pain. This project will use existing population-based cohorts, as well as establish a specific registry and biobank for patients with neuropathy in order to address these specific needs. This will allow the investigators to identify a large number of individuals with probable neuropathic pain and individuals with pain-free peripheral neuropathy (disease controls). International collaboration will contribute to study a large group of patients, which will be important in order to reach the project's goals. The results from the project are expected to increase current knowledge on the mechanisms of neuropathic pain, opening up new opportunities for innovative and improved treatments. Dissemination of results will be organized in close collaboration with patient representatives, and will be done regularly throughout the course of the project. The will focus both on internal dissemination to the participating hospitals, and external dissemination through participation in conferences, submissions to scientific journals and by publishing patient-friendly information booklets and proactively informing media outlets and patient organizations.
Interventions
GENETICNerve conduction Studies
Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
Sponsors
Haukeland University Hospital
Helse Stavanger HF
St. Olavs Hospital
University Hospital of North Norway
University of Oxford
Danish Pain Research Center
Oslo Metropolitan University
Oslo University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. The patient is between 18 and 70 years old. 2. The patient has consented. 3. The patient is referred for evaluation of possible distal symmetric polyneuropathy (DSPN). 4. The patient has filled out the questionnaires.
Exclusion criteria
1. The patient is too sick to participate (eg. bedridden, fever). 2. The patient is unable to consent (eg. dementia, speech problems, psychiatric disorder). 3. Inflammatory acute polyneuropathy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genetic variants associated with neuropathic pain. | Baseline | Relevant genotypes will be found using genome-wide association study (GWAS) methodology, ie. with no assumptions regarding which genetic variants that may be relevant (no hypotheses regarding specific variants). This is going to be conducted by using array genotyping (SNPs) in order to identify genetic variants that might be associated with neuropathic pain. Genetic variants will be defined and named according to standard practice, without any room for local or study specific adaptations. |
| Phenotype; neuropathic pain yes/no | Baseline | Patients will be divided in two groups; neuropathy With pain (= neuropathic pain) and neuropathy without pain. For definition of neuropathic pain, the Neupsig guidelines (Finnerup et al, Pain 2016) will be used.It is estimated that about 600 patients will be included yearly for this purpose |
| Phenotype; subgroup analysis of patients with neuropathic pain based on grading of pain | Baseline | Patients with neuropathic pain will be further subdivided in groups based on pain reports. Pain will be graded using validated questionnaires. The Brief Pain Inventory-BPI (Cleeland et al, 1994) questionnaire will be used as primary resource for pain grading, on a scale from 0 to 10 (0: no pain, 1-3: mild pain, 4-10: strong pain). |
Countries
Norway
Contacts
Primary ContactKristian B. Nilsen, M.D
Outcome results
None listed